H.C. Wainwright raised the firm’s price target on Omeros (OMER) to $20 from $9 and keeps a Buy rating on the shares after the company announced an asset purchase and license agreement with Novo Nordisk (NVO) for zaltenibart. Omeros will receive an upfront cash payment of $240M with potential for up to $510M in one-time development and approval milestone payments and up to $1.3B in one-time sales-based milestone payments, as well as tiered royalties on annual net sales of the products, the analyst tells investors in a research note. H.C. Wainwright cites the non-dilutive cash Omeros will receive and revised risk assumptions for zaltenibart for the target increase.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OMER:
- Unusually active option classes on open October 15th
- Omeros Signs Major Deal with Novo Nordisk
- Omeros up 124% at $9.20 after entering license agreement for zaltenibert
- Novo Nordisk, Omeros enter asset purchase, license agreement for zaltenibert
- Omeros Corporation Completes Promising Phase 2 Study on OMS906 for PNH